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Edited by Lev KisselevAbstract Patched homolog 1 (PTCH1) is a key component of
the Hedgehog (HH) signaling pathway with three alternative
ﬁrst exons, but only exon 1B transcription depending on HH
activation. Here, we show that in both human and mouse a novel
PTCH1 ﬁrst exon (1C) is expressed. Exon 1C transcription is
upregulated by HH signaling, but the resulting PTCH1-1C pro-
tein has a lower capacity for pathway inhibition than PTCH1-
1B.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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agonist1. Introduction
Hedgehog (HH) signaling is one of the major pathways for
developmental morphogenesis, and disturbances in this regula-
tory system may induce carcinogenesis and organismal malfor-
mation (see recent reviews, [1,2]). A number of components of
this pathway are known including the HH gene family (SHH,
IHH and DHH), Smoothened (SMO), the GLI gene family and
the Patched genes (PTCH1 and PTCH2) that act as negative
regulators of HH signaling. The binding of HH proteins to
PTCH allows activation of SMO and subsequently of tran-
scription factor GLI, resulting in upregulation of target genes.
Dysregulation of the inhibitory role of PTCH1 leads to mal-
formation and carcinogenesis, exempliﬁed by basal cell carci-
noma, medulloblastoma, and rhabdomyosarcoma [2–4]. The
role of PTCH1 during embryonic development has been inves-
tigated using knock out mice [5,6]. Ptch1/ mice have neural
tube defects and die during embryogenesis while Ptch1+/ mice
have skeletal defects and develop tumors, as is the case with
human heterozygotes.
Recently it has been found that over 74% of human genes
are characterized by alternative splicing variation, and at highAbbreviations: PTCH1, patched homolog 1; PTCH1-1, -1A, -B and
-1C, PTCH1 including the alternative ﬁrst exons 1, 1A, 1B and 1C,
respectively; HH, Hedgehog; SMO, smoothened; SAG, SMO agonist;
Hek293, human embryonic kidney cell line 293; FBS, fetal bovine
serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA,
haemagglutinin; GLIBS, GLI-binding site
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This suggests that a major pathway for the complexity of
expression of the human proteome may depend on the utiliza-
tion of alternative ﬁrst exons and consequently promoter re-
gions. In the case of the PTCH1 gene, we have previously
identiﬁed three unique ﬁrst exons by the use of the 5 0 RACE
methodology [3,8,9]. PTCH1-1B includes the alternative ﬁrst
exon 1B and encodes a full-length PTCH1 protein that can
completely inhibit SMO activity. PTCH1-1B does not repre-
sent a major transcript in human adult tissues but its expres-
sion is regulated by the HH signaling pathway, as
exempliﬁed by its upregulation in basal cell carcinoma [9,10].
The other ﬁrst exon variants are ubiquitously expressed in hu-
man adult tissues but are not aﬀected by HH signaling. Both
PTCH1-1 and PTCH1-1A encode the same short form of
PTCH1, which is translated from an ATG codon within exon
3. This short form can interact with HH family proteins just as
PTCH1-1B, but is incapable of fully suppressing HH signaling
[9].
Here, we present evidence for a novel ﬁrst exon of PTCH1,
named exon 1C, demonstrate that its expression is relatively
abundant in comparison with the other ﬁrst exon variants,
and moreover is upregulated by HH signaling. Additionally
PTCH1-1C can act as a pathway inhibitor. These ﬁndings
may provide new clues for a better understanding of the role
of PTCH1 in HH signal transduction.2. Materials and methods
2.1. Tissue distribution analysis
Pairs of initial or nested primers were designed for each PTCH1
alternative ﬁrst exon. The sequence of the primers used is given in Ta-
ble 1. Multiple tissue cDNA panels from BD Biosciences (CA, USA)
were used with the primers obtained from Cybergene AB (Huddinge,
Sweden). Each reaction consisted of 1· buﬀer B (MBI Fermentas, Vil-
nius, Lithuania), 2 mM MgCl2, 0.2 mM for each dNTP, 0.5 lM for-
ward primers for each alternative ﬁrst exon, 1.0 lM reverse primer
for exon 2, 1.0 ll of Taq DNA polymerase (5 units/ll, MBI Fermen-
tas), and 1 ng of cDNA in a total volume of 25 ll. Thirty cycles with
30 s at 95 C, 30 s at 54 C, and 1 min at 72 C were performed on a
Perkin–Elmer thermocycler. For nested PCR, 0.5 ll of the initial
ampliﬁcation products was used. Ampliﬁcations without exogenous
cDNA were used in all sets of experiments as a negative control.
The nested products were analyzed on a 4% NuSieve 3:1 agarose gel
(FMC BioProducts, ME, USA). All PCR products were sequence-ver-
iﬁed (Cybergene AB).2.2. Cell culture and expression analysis
The human embryonic kidney cell line (Hek293) and the murine
ﬁbroblast cell line NIH3T3 were cultured as described before [10].ation of European Biochemical Societies.
Table 1
Sequence of the PCR primers used
Human Mouse
E1-F 5 0-CAGCGCCGGGGAAATG 5 0-AGAGCAGCCTGCGCCCA
E1-F nested 5 0-TCCCTTTGCACTCOGCT 5 0-TCCTTGTGCACTCGGCT
E1A-F 5 0-ACCACGTGGATCCCCAC 5 0-CACCACGTGGACCTCGC
E1A-F nested 5 0-GGGGGAACCCGCAATAT 5 0-GACCACGGTTGCTGTAGA
E1B-F 5 0-AGCGGCTGTATCGGTGC 5 0-GGCCTCGGCTGGTAACG
E1B-F nested 5 0-GACCGGGACTATCTGCA 5 0-GACCGGGACTATCTGCA
E1C-F 5 0-GGCCATGGAACTGCTTAATA 5 0-GGCCATGGACCTGCTTAATA
E1C-F nested 5 0-GACGACAGGGGAGACAAAG 5 0-GGCGACAGGGCAGACAAAG
E2-R 5 0-TGAGOAGGCCCACAACC 5 0-TGAGGAGACCCACAACC
E2-R nested 5 0-TTCGCTCTCAGCCACAG 5 0-TTCGCTCTCAGCCACAG
GAPDH-F 5 0-ACAACAGCCTCAAGATCATCA 5 0-ACAACTCACTCAAGATTGTCA
GAPDH-R 5 0-GTCCACCACTGACACGTTG 5 0-ATCCACGACGGACACATTG
158 T. Shimokawa et al. / FEBS Letters 578 (2004) 157–1625 · 105 NIH3T3 cells were plated on 10 cm dishes. One day later, the
medium was changed to DMEM containing 0.5% fetal bovine serum
(FBS) with or without 100 nM SAG (SMO agonist, provided by Dr.
Jan Bergman, Karolinska Institute). After incubation for 48 h, total
RNA was isolated by the RNeasy kit (QIAGEN GmbH, Hilden, Ger-
many) according to the manufacturers instructions.
For reverse transcription, 5 lg of total RNA, 4 ll of a 2.5 mM
dNTP mixture (2.5 mM each), and 0.5 ng of oligo (dT)18(A/C/G)(A/
C/G/T) primer in a total volume of 12 ll were denatured at 65 C
for 5 min. After cooling the mixture on ice, 4 ll of 5·RT buﬀer, 2 ll
of 0.1 M DTT, and 1ll of Ribonuclease Inhibitor (TAKARA BIO,
Shiga, Japan) were added. After incubation at 45 C for 2 min, 1 ll
of Superscript RT (Invitrogen) or water (negative control) was added.
Then the mixture was incubated at 45 C for 90 min. The reaction was
stopped by heat inactivation at 75 C for 15 min. The amount of sin-
gle-stranded cDNA used for subsequent PCR ampliﬁcation was equal-
ized by monitoring the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene expression as a quantitative control (Table 1). PCR
analysis was performed using the same conditions as for tissue distri-
bution analysis but with mouse-speciﬁc primers (Table 1).
2.3. Expression of cDNA constructs in mammalian cells
For construction of the PTCH1-1C expression plasmid, we ﬁrst per-
formed a PCR ampliﬁcation using the Expand PCR System (Roche
Diagnostics, Basel, Switzerland) on IMAGE-5170834 clone (MRC-
geneservice, Cambridge, UK), with PTCH1 speciﬁc primer set
(5 0-GCGGCTAGCCGGCCGCGGGGGGC and 5 0-GCGCCTAGG-
AGGTATGCTGTCCCAGACT). The PCR product and a full-length
3 0-FLAG-tagged PTCH1-1B expression plasmid were digested with
NheI and AvrII restriction enzymes and then ligated allowing the N-
terminal region of PTCH1-1B to be replaced by the PCR product con-
taining exon 1C (starting at nucleotide positions 1 of exon 1C). The
construct was veriﬁed by sequencing.
The other expression constructs used have been described in previ-
ous reports, the full-length 3 0-FLAG-tagged PTCH1 constructs with
the alternative ﬁrst exons, 1 and 1B [9], the HA (haemagglutinin)-
tagged human full-length GLI1 [11], and the activated human SMO-
M2 [12].
Expression constructs for PTCH1 splice variants and other pathway
components were transfected into human embryonic kidney Hek293
cells and murine NIH3T3 cells using FuGENE 6 (Roche Diagnostics).
Western blotting were performed as previously described [9,13]. The
polyclonal antibodies to FLAG epitopes were purchased from Strata-
gene (CA, USA).
2.4. Reporter assays
To examine the activity of the PTCH1 exon 1C promoter, we PCR
ampliﬁed four fragments, each corresponding to part of the region
around exon 1C (Fig. 2A). PCR reactions were performed using the
Expand PCR System and a BAC clone (RP11-43505, BACPAC Re-
sources, CA, USA) harboring the human PTCH1 gene. Plasmids B1
and B2 were constructed by ampliﬁcation of B1-F (5 0-GCGG-
CTAGCGGAGCAAATGTCAATCCGT) or B2-F (5 0-GCGGCT-
AGCCGGCCGCGGGGGGC), with the same reverse primer
(B-R; 5 0-GCGAGATCTAAGCAGTTCCATGGCCCT). Site-directedmutagenesis of the putative GLI1 binding site was carried out by
replacing GACCACCCA to GACGTGGGA using mut-primer (5 0-
GTTCCATGGCCCTCGGCGTCCCACGTCTGCCGCG). The four
PCR products were ligated into the pGL3-basic luciferase reporter vec-
tor (pGL3B, Promega, WI, USA). To generate constructs P1 and
P1mut, double-stranded DNAs were prepared by annealing wild-F
(5 0-CTAGCTGGCGCGGCAGACCACCCACGCCGAGGGCA) to
wild-R (5 0-GATCTGCCCTCGGCGTGGGTGGTCTGCCGCGC-
CAG) or mut-F (5 0-CTAGCTGGCGCGGCAGACGTGGGACGC-
CGAGGGCA) to mut-R (5 0-GATCTGCCCTCGGCGTCCCA-
CGTCTGCCGCGCCAG) and cloned into the NheI and BglII sites
of the pGL3-promoter vector (pGL3P, Promega). All constructs were
veriﬁed by sequencing. 8xGLIBS-luc and 8xmGLIBS-luc were pre-
pared as described elsewhere [14].
Conﬂuent cultures of NIH3T3 cells were trypsinized and plated at
1:6 dilution on 24-well plates. The next day, cells were transfected with
0.5 lg of PTCH1 exon1C-luciferase reporter plasmids (B1, B2, B1mut,
B2mut, P1 or P1mut), 0.5 lg of expression constructs (HA-tagged hu-
man GLI1 or pCMV5) and 50 ng of Renilla luciferase (pRL-SV40) as
transfection control. For the functional analysis of the PTCH1 splice
variants, cells were transfected with 0.25 lg of luc reporter
(8xGLIBS-luc or 8xmGLIBS-luc), 0.25 lg of expression constructs
(HA-tagged human GLI1, N-terminal SHH or activated SMO-M2)
and 50 ng of pRL-SV40 with or without 0.5 lg of PTCH1 expression
constructs (FLAG-tagged PTCH1-1, PTCH1-1B, or PTCH1-1C). 3 ll
of FuGENE 6 transfection reagent were always used. After 24 h, the
medium was changed to a low-serum medium (0.5% FBS), and cells
were allowed to grow for an additional 1 or 2 days before harvesting.
Normalized luciferase activity was determined with the dual-luciferase
reporter assay system (Promega) using the FB12 Luminometer (Bert-
hold Detection System, Pforzheim, Germany) according to the sup-
pliers recommendations. All experiments were repeated
independently at least three times and measurements in each experi-
ment were performed at least twice.3. Results
3.1. In silico screening for PTCH1 splicing variations
To identify novel splice variants in HH signaling compo-
nents, we screened EST sequences from the web-available dat-
abases, GRL (Gene Resource Locator, http://grl.gi.k.u-tokyo.
ac.jp/) [15], EASED (Extended Alternatively Spliced EST
Database, http://eased.bioinf.mdc-berlin.de/) [16], ASAP (The
Alternative Splicing Annotation Project, http://www.bioinfor-
matics.ucla.edu/ASAP/) [17] and NCBI (National Center for
Biotechnology Information). Among many candidates, a hu-
man EST for PTCH1 (IMAGE-5170834) was noted. This
EST comprised of PTCH1 sequences (NM_000264) from exon
2 to exon 5, and of unknown sequences (589 nucleotides) up-
stream of exon 2. The unknown sequences were found to com-
pletely match with human genomic DNA that locates about 10
T. Shimokawa et al. / FEBS Letters 578 (2004) 157–162 159kb upstream of PTCH1 exon 2 and thus were named exon 1C
(Fig. 1A). The DNA sequence of this region is highly con-
served between human and mouse (Fig. 1B) and the exon-in-
tron boundary at the 3 0 end of exon 1C retains the
consensus 5 0 splice sequence (exon 1C    TG/gtgagt   
intron). To conﬁrm the expression of exon 1C, we made for-
ward primers for each of PTCH1 ﬁrst exon (1, 1A, 1B, and
1C) and reverse primers for exon 2 and compared the expres-
sion pattern of the PTCH1 splice variants [9] using cDNA pan-
els (Fig. 1C). As reported previously, exons 1 and 1A were
expressed ubiquitously in all eight human adult tissues tested.
Since exon 1B expression is lower than that of 1 and 1A [9], it
was diﬃcult to detect it under the experimental conditions
used. Exon 1C expression was observed in human brain, pla-
centa, lung, kidney and pancreas.
In contrast to the relative similar expression of the PTCH1
variants in adult tissues, a signiﬁcant tissue speciﬁcity was ob-
served in human fetal tissues, highlighting the likely impor-
tance of exon 1 variation during early development. These
results clearly demonstrated that PTCH1 can express exonFig. 1. Gene structure and expression of PTCH1 exon 1C. (A) Genomic str
Exons are represented by black boxes with the splicing pattern indicated. (B)
regions (underlined in panel A) between human and mouse. White boxes re
position in human indicated. The position of the CpG islands identiﬁed is al
exons. The RT-PCR methodology with primers for each of the ﬁrst exons and
follows: Exon 1C, 233 bp; Exon 1B, 122 bp; Exon 1A, 192 bp; Exon 1, 1411C and that this transcript appears to be the major one in sev-
eral tissues.
3.2. Regulation of expression of PTCH1 ﬁrst exons by the
Hedgehog signaling pathway
It is known that the expression of exon 1B is upregulated by
HH signaling. To examine the relationship between the expres-
sion of exon 1C and HH signaling, we searched for consensus
GLI1-binding motifs, 5 0-GACCACCCA within a 2 kb genomic
segment that includes exon 1C and its 5 0 ﬂanking region and
identiﬁed one candidate site at position +218 to +226 (GLI-
binding site, GLIBS; Fig. 2A) of the EST clone. This ﬁnding
of a GLIBS in the 5 0-untranslated region suggests the possibil-
ity that PTCH1-1C expression may also be regulated by HH
signaling. Notably, the GLIBS sequence was found to be fully
conserved in the corresponding region of mouse Ptch1, in line
with the signiﬁcant similarity of the alternative ﬁrst exons in
the two species. To verify that this is indeed the case, we com-
pared the expression of the Ptch1 ﬁrst exons in NIH3T3 cells
with or without SAG, a chlorobenzothiophene-containingucture of the PTCH1 region that includes the ﬁrst exons and exon 2.
Comparison of the genomic DNA sequence of exon 1C and its ﬂanking
present highly conserved regions with percent identity and nucleotide
so shown. (C) Tissue speciﬁc expression of the alternative PTCH1 ﬁrst
for exon 2 was used. The predicted size of the RT-PCR fragments is as
bp.
Fig. 2. Regulation of PTCH1 exon 1C expression. (A) Presence of a
GLIBS in the exon 1C region. The black box indicates the exon 1C.
The putative GLIBS is shown above the black box and its nucleotide
position indicated. The structure of the regulatory constructs gener-
ated (B1, B2, B1mut, B2mut, P1, and P1mut) is also shown with X
indicating the mutation of the GLIBS. (B) Up-regulation of the
PTCH1 mRNAs including exons 1C or 1B by SAG treatment.
NIH3T3 cells were incubated with or without SAG and expression of
the Ptch1 ﬁrst exons was determined by RT-PCR. (C) Eﬀects of GLI1
expression on the exon 1C promoter activity. NIH3T3 cells were
transfected with a GLI1 expression construct as well as with each of
the reporter constructs of panel A.
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from exon 1C was upregulated after treatment with SAG, as
also observed for exon 1B. The expression from either exon 1
or 1A was not aﬀected by SAG.
To examine whether the identiﬁed GLIBS might be respon-
sible for the HH signaling activation of this promoter, we
cloned various fragments from this region upstream of the
luciferase gene and performed reporter assays using NIH3T3
cells (Fig. 2A and C). As expected, constructs B1, B2, and
P1 stimulated luciferase activity approximately 2-fold after
overexpression of GLI1 protein, while mutations of the GLIBS
(constructs B1mut, B2mut, and P1mut) suppressed the GLI1
stimulation. These results suggested that the identiﬁed GLIBS
functions as a cis-element responsible for the signaling-depen-
dent expression of exon 1C.
3.3. Functional properties of PTCH1 proteins with alternative
N-terminal domains
The deduced amino acid sequence of PTCH1-1C indicates
that translation initiates at an ATG codon at the very end of
exon 1C (positions +587 to +589 of the EST clone). Therefore
the putative PTCH1-1C protein lacks 67 amino acids from the
N-terminal tail of PTCH1-1B. PTCH1-1 and PTCH1-1A are
considered to initiate translation from an ATG codon in exon3, and thus lack not only the N-terminal tail but also the ﬁrst
transmembrane region.
To better understand the biological function of the expressed
ﬁrst exons of the PTCH1 gene, we also made a FLAG-tagged
PTCH1-1C expression construct. The PTCH1 splice variants,
after transfection into Hek293 cells, were solubilized by a lysis
buﬀer containing 1% NP-40 and Western blot analysis indi-
cated that the level of PTCH1-1C is comparable with the other
splice variants. Unexpectedly, subsequent solubilization of the
pellet by a lysis buﬀer containing 1% SDS showed that
the majority of PTCH1-1B and PTCH1-1C was localized in
the NP-40 insoluble fraction and this contrasts PTCH1-1.
Moreover the level of PTCH1-1B in the pellet was higher than
that of PTCH1-1C (Fig. 3A).
To further investigate the localization of the PTCH1-1C
protein in mammalian cells, we also transiently transfected
the FLAG-tagged PTCH1 splice variants into Hek293 or
NIH3T3 cells and observed the expressed proteins by immuno-
ﬂuorescence staining. Microscopic analysis indicated a primar-
ily cytoplasmic localization with no major diﬀerences among
the proteins tested (data not shown).
PTCH1 acts as a negative regulator of the HH signaling
pathway, however the eﬀectiveness of this inhibition depends
on which ﬁrst exon is expressed [9]. To compare the capacity
of PTCH1-1C to downregulate signaling relative to other
splice variants, we performed functional assays utilizing a
8xGLIBS-luc reporter construct and overexpressing SMO in
NIH3T3 cells [9,14]. As reported previously, PTCH1-1B could
fully inhibit SMO activation. PTCH1-1C could also inhibit sig-
naling two days after transfection but lost this capacity after
an additional day in cell culture, while PTCH1-1B did not
(Fig. 3B). These results suggest that the N-terminal tail of
PTCH1 and more speciﬁcally the 67 terminal amino acids have
a critical role for the negative regulation of HH signaling.4. Discussion
In this report, we demonstrated the presence of a novel
PTCH1 ﬁrst exon conserved in both human and mouse, whose
expression is regulated by the HH signaling pathway.
We have already reported the existence of three PTCH1 ﬁrst
exon variants and examined their functional diﬀerences [9,10].
These three ﬁrst exons are located at a narrow region, approx-
imately 2 kb upstream of exon 2 in the human and mouse gen-
ome. PTCH1-1 and PTCH1-1A mRNAs encode short forms of
PTCH1 that lack the N-terminal tail and the ﬁrst transmem-
brane region. As shown here and in previous reports, expression
of these ﬁrst exons tends to be observed ubiquitously in human
adult tissues. PTCH1-1B mRNA encodes the longest form of
PTCH1. Its expression is regulated by the HH signaling path-
way, therefore has only been observed in tissues or cells that
are exposed to HH ligands. On the other hand, the novel ﬁrst
exon of PTCH1, exon 1C, is uniquely located about 10 kb up-
stream of PTCH1 exon 2, and allows the synthesis of a PTCH1
protein lacking part of the N-terminal tail. Additionally, exon
1C expression is also activated by the HH signaling pathway.
Functional analysis of PTCH1 revealed dramatic diﬀerences
in both the capacity of PTCH1-1, PTCH1-1B and PTCH1-1C
to downregulate signaling as well as in the duration of these ef-
fects. Although we could not detect a sharp contrast in cellular
localization by immunoﬂuorescence staining, Western blot
Fig. 3. Functional properties of PTCH1-1C. (A) Expression of exogenous PTCH1 splice variants in Hek293 cells. Western blotting was performed
using the anti-FLAG antibody. Note that all variants are expressed at comparable levels in the NP-40 soluble fraction (supernatant) however the
majority of PTCH1-IB and PTCH1-1C is present in the insoluble fraction (pellet) and is detected after subsequent solubilization by SDS. (B)
Inﬂuence of overexpression of PTCH1 splice variants on SMO activation of a GLI reporter construct. The luciferase activity was measured at either 2
days (left panel) or 3 days (right panel) after transfection.
T. Shimokawa et al. / FEBS Letters 578 (2004) 157–162 161analysis indicated that the total amount and the solubility of
PTCH1 are aﬀected by the structure of the N-terminal region.
Our results suggest that the role of the N-terminal domain is
not only in suppressing HH signaling, but may also regulate
PTCH1 solubility and expression levels. Moreover the fact that
downregulation of HH signaling parallels increased protein
expression and decreased solubility suggests that these proper-
ties could be interconnected. However, at this point the exact
role of translational regulation, protein stability and/or inher-
ent capacity of SMO downregulation can not be determined.
In any case our data support the possibility that the expression
of alternative ﬁrst exon splice variants is a regulatory system
for HH signaling during development in the embryo and/or
homeostasis in adult tissues. An outline of the unique features
of each of the PTCH1 exon 1 variants is given in Table 2.Table 2




Inﬂuence of HH signaling
Conservation of DNA sequence between human and mouse High
PTCH1
Position of 1st ATG Exon 3
1st Transmembrane domain No
N-terminal tail No
Subcellular localization
Solubilization by 1% NP-40 Superna
Supernatant protein level Low
Pellet protein level Low
Inhibition of HH signaling WeakPreviously, we have reported that the PTCH1 paralogue,
PTCH2, expresses a splice variant lacking exon 9 and/or exon
10 [19]. This region is part of a conserved sterol-sensing do-
main and aﬀects the inhibitory properties of PTCH2. PTCH1
splice variants lacking this same region are also expressed in
mammalian cells [20] (Rahnama, F., et al., unpublished data).
This provides additional evidence that HH signaling may be
controlled by a more complex system than originally thought,
involving regulated splicing variations.
In the past, despite the fact that exon 1B expression does not
represent the major transcriptional output of PTCH1 com-
pared to exons 1 or 1 A, the role of PTCH1 in disease or devel-
opmental morphogenesis was centered only on the exon 1B
transcript. Certainly, we realize that mRNA levels may not di-
rectly relate to protein levels, and moreover PTCH1-1B has thenique PTCH1 ﬁrst exons and the corresponding protein products





-1 (PTCH1-1A) PTCH1-1B PTCH1-1C
Exon 1B Exon 1C
Yes
Yes Yes, but lack of 67 a.a.
Cytoplasm




162 T. Shimokawa et al. / FEBS Letters 578 (2004) 157–162highest capacity to inhibit the HH signaling pathway. One pos-
sibility is that PTCH1-1B is the form that is involved in the
feedback loop that down regulates signaling, while 1 and 1A
may generally act to limit the spreading of the HH signal.
PTCH1-1C could have a role in both scenarios. Downregulat-
ing signaling may represent a ﬁrst response while limiting li-
gand spreading may reﬂect a secondary event. Unraveling
the role of PTCH1 in development and disease will certainly
require further investigations into the details of the function
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